



ARMOR:

Empowering Hope Through Gene Therapy for ALS

Be a Part of the Mission to Transform ALS Treatment



Learn More

ARMOR is now open and recruiting.
For eligibility requirements, study locations and
contact details, see **ALSARMOR.COM**



ARMOR is a Phase 1 trial being conducted to get more information about the study drug, called INS1202, as a potential treatment for ALS.

The main goal of this study is to find the right dose of investigational compound INS1202 and to check how safe and tolerable it is when given as a single injection into the spinal fluid. We are looking at how the investigational compound INS1202 works in the body. This study is for people aged 18 to 79 who have ALS, a disease affecting nerve cells, and either have a specific genetic change called SOD1 mutation or do not have any known genetic changes related to ALS.

How will INS1202 be given?



ARMOR is a first-in-human investigational research study designed to assess the safety of INS1202.



INS1202 is given as a one-time IT injection. This means that the medication is delivered directly into the fluid-filled space around the spinal cord.



The potential effect of INS1202 will be assessed using a biomarker for nerve damage and physical function tests.



The study will last around a year, with an additional follow-up period of four years.

How do I know if I can take part in the study?

Eligibility information

1

Age

18 to 79 years of age (both inclusive).

2

ALS Diagnosis

Diagnosed with amyotrophic lateral sclerosis (ALS) with or without SOD1 mutations.

3

Disease duration

Symptomatic ALS with disease duration less than or equal to 42 months.

4

Able to swallow pills

Corticosteroids will be dispensed and taken daily for approximately 8 weeks

5

Sporadic ALS

Negative testing for known mutations associated with familial ALS

OR

6

SOD1-ALS

SOD1 mutation with no other genetic mutations associated with familial ALS



Learn More



To learn more about the ARMOR study, please contact Insmed Medical Information. For full details of the study, see **ALSARMOR.COM**